Vitamin B 12 in the treatment of chronic hepatitis C
Not Applicable
- Conditions
- Chronic hepatitis C.Chronic viral hepatitis C
- Registration Number
- IRCT201508064226N3
- Lead Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Exclusion criteria: age <18 or>70 year, previous treatment with interferon and ribavirin, concomitant causes of liver disease, such as hepatitis B virus infection, autoimmunity and alcohol abuse (>40 g/day for men and >20 g/day for women),
HIV infection, hepatocellular carcinoma, decompensated cirrhosis, severe concurrent disease, contraindications to treatment.
age between 18 to70 years, Lack of concomitant causes of liver disease, such as hepatitis B virus infection, autoimmunity and alcohol abuse (>40 g/day for men and >20 g/day for women), Lack of HIV infection, Lack of hepatocellular carcinoma, Lack of decompensated cirrhosis, Lack of severe concurrent disease.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sustained Virologic Response. Timepoint: 6 months after treatment course. Method of measurement: copy of virus in ml of serum.
- Secondary Outcome Measures
Name Time Method Serum viral load. Timepoint: baseline-3months-6months- end of treatment. Method of measurement: Copy of virus per mililiter.;Liver enzymes. Timepoint: baseline-3months-6months- end of treatment- 6 months after treatment course. Method of measurement: miligram per deciliter of serum.